Factors Associated with Delayed Thrombolytic Medication among Patients with ST-Segment Elevation Myocardial Infarction in Southern Thailand

Background: ST-Segment Elevation Myocardial Infarction (STEMI) is among the most prevalent heart diseases worldwide and a leading cause of death. Delayed thrombolytic treatment significantly increases mortality risk in affected patients. This study aimed to identify factors associated with delayed administration of thrombolytic medication in STEMI patients. Methods: A cross-sectional analytical study was conducted in Narathiwat Province, involving 1,074 STEMI patients documented in the Acute Coronary Syndrome Registry between January 1, 2016, and December 31, 2021. Of these, 781 eligible patients were categorized into two groups: 464 with delayed thrombolytic medication and 317 without. Descriptive statistics and multiple logistic regression used for data analysis. Results: The proportion of patients experiencing delayed thrombolytic medication was 59.4% (95% CI: 55.8-62.9). Factors such as the total number of underlying diseases, Killip classification, and timing of accessing health services were associated with delayed thrombolytic medication. Patients with four underlying diseases had a reduced risk of delayed thrombolytic medication (AOR = 0.40, 95% CI: 0.24-0.63). Conversely, those diagnosed with cardiogenic shock (Class IV) (AOR = 3.74, 95% CI: 1.94-7.20) and those accessing services at night increased risk of delayed thrombolytic mediation (AOR = 2.16, 95% CI: 1.37-3.40). Conclusion: The number of underlying diseases, Killip classification, and timing of health service access were linked to delayed thrombolytic medication. STEMI patients with advanced Killip classification, particularly those seeking care at night, should receive intensified attention to ensure timely administration of thrombolytic, thereby mitigating disease progression and reducing mortality. Keywords: Delayed Thrombolytic Medication, ST-elevation myocardial infarction, Thrombolytic therapy, Thailand

Authors

Publication Details

Journal
Journal of Health Research
Published
2025-03-13
DOI
https://doi.org/10.56808/2586-940x.1121
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Factors Associated with Delayed Thrombolytic Medication among Patients with ST-Segment Elevation Myocardial Infarction in Southern Thailand

Somkiattiyos Woradet, Bhunyabhadh Chaimay, Mamaphoasee Suemae
Journal of Health Research
Health Systems, Economic Evaluations, Quality of Life
article

Factors Associated with Delayed Thrombolytic Medication among Patients with ST-Segment Elevation Myocardial Infarction in Southern Thailand

Somkiattiyos Woradet, Bhunyabhadh Chaimay, Mamaphoasee Suemae
article en

Abstract

Background: ST-Segment Elevation Myocardial Infarction (STEMI) is among the most prevalent heart diseases worldwide and a leading cause of death. Delayed thrombolytic treatment significantly increases mortality risk in affected patients. This study aimed to identify factors associated with delayed administration of thrombolytic medication in STEMI patients. Methods: A cross-sectional analytical study was conducted in Narathiwat Province, involving 1,074 STEMI patients documented in the Acute Coronary Syndrome Registry between January 1, 2016, and December 31, 2021. Of these, 781 eligible patients were categorized into two groups: 464 with delayed thrombolytic medication and 317 without. Descriptive statistics and multiple logistic regression used for data analysis. Results: The proportion of patients experiencing delayed thrombolytic medication was 59.4% (95% CI: 55.8-62.9). Factors such as the total number of underlying diseases, Killip classification, and timing of accessing health services were associated with delayed thrombolytic medication. Patients with four underlying diseases had a reduced risk of delayed thrombolytic medication (AOR = 0.40, 95% CI: 0.24-0.63). Conversely, those diagnosed with cardiogenic shock (Class IV) (AOR = 3.74, 95% CI: 1.94-7.20) and those accessing services at night increased risk of delayed thrombolytic mediation (AOR = 2.16, 95% CI: 1.37-3.40). Conclusion: The number of underlying diseases, Killip classification, and timing of health service access were linked to delayed thrombolytic medication. STEMI patients with advanced Killip classification, particularly those seeking care at night, should receive intensified attention to ensure timely administration of thrombolytic, thereby mitigating disease progression and reducing mortality. Keywords: Delayed Thrombolytic Medication, ST-elevation myocardial infarction, Thrombolytic therapy, Thailand

Journal of Health ResearchVol. 39(1)
Openalex Percentile: Top 93%
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.